<DOC>
	<DOCNO>NCT01864759</DOCNO>
	<brief_summary>The investigator evaluate safety single endovenous infusion ICOVIR5 adult locally advance metastatic melanoma . ICOVIR5 consist conditionally replicative oncolytic adenovirus .</brief_summary>
	<brief_title>Phase I Endovenous Administration Oncolytic Adenovirus ICOVIR-5 Patients With Advanced Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<criteria>Malignant melanoma advance metastatic . Other 18 year Karnofsky index &gt; 60 % Life expectancy &gt; 3 month ALT/AST &lt; =2.5 time upper normal limit Creatinine clearance &gt; = 50 ml/min . Bilirubin &lt; 25 umol/l Alkaline phosphatase &lt; = 2.5 time upper normal limit Normal bone marrow function : Neutrophils &gt; =1.5 E9/L , platelets &gt; = 1E11/L , hemoglobin &gt; = 100 g/l , Normal prothrombin time thromboplastin time , HIV negative Measurable disease Signed informed consent . Geographical , social psychological condition may impair protocol compliance . Active infection severe medical status . History liver disease . Other concomitant treatment melanoma investigational product . Previous participation study adenovirus . Virus disease diagnose two week inclusion . Immunosuppressive concomitant treatment Concomitant malignant haematological disease . Patients family member immunodeficient status disease Patients Li Fraumeni syndrome germinal retinoblastoma gene defect .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>melanoma</keyword>
	<keyword>oncolytic</keyword>
	<keyword>adenovirus</keyword>
	<keyword>virotherapy</keyword>
	<keyword>locally advanced</keyword>
	<keyword>metastatic</keyword>
</DOC>